8-K: Zynex Submits FDA Application for NiCO Laser Pulse Oximeter, Aiming to Revolutionize Patient Monitoring

Zynex, Inc. has submitted a 510(k) application to the FDA for its NiCO, Noninvasive CO-Oximeter device, a laser-based pulse oximeter designed to improve accuracy and address limitations of current devices.

Summary

• Zynex has submitted a 510(k) application to the FDA for its NiCO, a non-invasive CO-Oximeter device.
• The NiCO device uses laser technology to measure oxygen levels accurately, even in patients with dark skin pigmentation.
• It also measures carbon monoxide levels, potentially reducing the need for blood samples.
• The device addresses inaccuracies found in traditional LED-based pulse oximeters, especially concerning measurements in individuals with darker skin.
• The NiCO measures oxygenated hemoglobin, reduced hemoglobin, carboxyhemoglobin, and methemoglobin.
• The estimated accessible market for pulse oximetry monitoring is over $2.8 billion today, growing to $4.3 billion in 2027.

Sentiment

Score: 8

Explanation: The document is positive due to the submission of the FDA application for a potentially groundbreaking device. The company highlights the device's advantages over existing technology and its potential to improve patient care. The large and growing market size also contributes to the positive sentiment.

Positives

• The NiCO device uses laser technology, which is more accurate than traditional LED-based pulse oximeters, especially for patients with dark skin.
• The device can measure multiple hemoglobin species, providing a more complete picture of a patient's oxygen status.
• The NiCO device has the potential to reduce the need for blood samples in cases of carbon monoxide poisoning.
• The pulse oximetry market is large and growing, with an estimated accessible market of over $2.8 billion today, growing to $4.3 billion in 2027.
• The NiCO submission is an exciting first step in creating a new standard for patient monitoring.

Risks

• The FDA may not approve the 510(k) application for the NiCO device.
• The device may not be accepted by doctors and hospitals.
• Zynex faces competition from larger companies with greater financial resources.
• The company needs to keep pace with technological changes.
• Zynex depends on reimbursement for its products from health insurance companies.
• Zynex depends on first party manufacturers to produce its products on time and to its specifications.
• The company's sales strategy may not be successful.
• Economic factors, such as interest rate fluctuations, could negatively impact the company.

Future Outlook

The company believes NiCO is a distinct market disrupting technology and can provide significant improvements to patient care for hospital and non-hospital providers in numerous medical settings. Laser pulse oximetry has the promise to revolutionize not only oxygen saturation measurements, but also the total hemoglobin testing market which is another $2-34 billion market opportunity that Zynex can pursue with laser-based technology.

Management Comments

• Donald Gregg, President of Zynex Monitoring Solutions, stated that the NiCO Laser Pulse Oximeter is groundbreaking in providing more reliable, comprehensive, and accurate information about a patient's oxygen status.
• Thomas Sandgaard, Zynex Founder and CEO, said that the 510(k) submission marks a major breakthrough on the path to changing the landscape of patient monitoring.

Industry Context

The announcement comes amid increased scrutiny of pulse oximetry accuracy, particularly concerning variations in measurements among individuals with different skin pigmentations. The FDA has issued updated recommendations urging device manufacturers to address this issue. Zynex's laser-based technology aims to provide a solution to this problem.

Comparison to Industry Standards

• Traditional LED-based pulse oximeters, such as those produced by Masimo and Medtronic, have faced criticism for inaccuracies, especially in patients with darker skin pigmentation.
• The NiCO device aims to surpass these limitations by using laser technology to directly measure fractional blood oxygenation levels, unlike the estimation of functional oxygen saturation (SpO2) used by current LED technology.
• The company believes that the NiCO device will be the first product to accurately and continuously measure all four primary hemoglobin species via patented laser pulse oximetry technology, to enable earlier and more accurate detection of hypoxia and hyperoxia.
• The total hemoglobin testing market is another $2-34 billion market opportunity that Zynex can pursue with laser-based technology.

Stakeholder Impact

• Shareholders may benefit from the potential success of the NiCO device.
• Clinicians may have access to a more accurate and reliable tool for monitoring patient oxygen levels.
• Patients may experience improved care and outcomes due to the device's enhanced accuracy.

Next Steps

• The company awaits the FDA's decision on the 510(k) application for the NiCO device.
• Zynex will continue to develop, manufacture, market, and sell medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals.

Key Dates

Keywords

pulse oximetry, NiCO, FDA, Zynex, laser technology, patient monitoring, CO-Oximeter, hypoxia, hyperoxia, hemoglobin